Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment

Ankur Banerjee  |  February 10, 2017

(Reuters)—U.S. Sen. Claire McCaskill (D-Mo.) on Thursday asked Kaleo Pharmaceuticals to justify the more than 550% surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag. Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately…

Filed under:Drug Updates Tagged with:costsdrug pricingDrugsnaloxoneOpioid abuseOpioids

Physicians Asked to Join AMA Efforts to Reduce Opioid Abuse

Mary Beth Nierengarten  |  October 31, 2016

In 2014, the American College of Rheumatology (ACR) was one of 25 healthcare associations invited to participate in an initiative by the American Medical Association (AMA) to reduce the public health epidemic posed by the abuse of prescription opioids.1 The AMA initiative is based on the belief that physicians are professionally obligated to participate in…

Filed under:EthicsProfessional Topics Tagged with:American Medical Association (AMA)Opioid abuseopioid use disordersPrescription drugssubstance abuse disorderstask force

Cigna Ends Preauthorization Requirement to Treat Opioid Addiction

Reuters Staff  |  October 22, 2016

(Reuters)—Health insurer Cigna Corp. has discontinued its policy of requiring doctors to seek authorization before treating opioid addicts, as part of a fight against an epidemic of opioid abuse, New York Attorney General Eric Schneiderman said on Friday. The policy change will apply nationally, says Schneiderman, who has been pushing for easier access to treatments…

Filed under:Legal Updates Tagged with:Cigna Corp.DrugsHealth InsuranceHealthcareOpioid abuseOpioids

FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

Michele B. Kaufman, PharmD, BCGP  |  October 5, 2016

Due to serious side effects from the combined use of opioids and benzodiazepines, the FDA has issued boxed warnings for both types of medication…

Filed under:AnalgesicsDrug Updates Tagged with:benzodiazepinesDrug SafetyDrug Safety Labeling Changes (SLC) databaseFDAFood and Drug AdministrationOpioidssafety warning

U.S. Justice Department to Push Prosecutors on Opioids

Reuters Staff  |  September 18, 2016

WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…

Filed under:AnalgesicsDrug Updates Tagged with:Department of JusticeOpioidsOverdosePain

FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2016

FDA advisory committees recommend the approvals of the abuse-deterrent opioid morphine sulfate for pain and brodalumab for plaque psoriasis…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationmorphine sulfateOpioidsPainplaque psoriasis

Senior Drivers Taking Opioid Painkillers Have Higher Crash Risk

Linda Thrasybule  |  August 14, 2016

(Reuters Health)—Seniors who get behind the wheel soon after starting to use narcotic pain relievers have twice the risk of getting into a serious car crash as their peers who use non-opioid painkillers, Swedish researchers say. Senior drivers who’d been using opioid painkillers regularly for several months also had higher odds of getting into accidents,…

Filed under:AnalgesicsDrug Updates Tagged with:elderlyOpioidsPainPain Managementsenior

Most Seniors Won’t Abuse Opioids After Surgery

Andrew M. Seaman  |  August 13, 2016

(Reuters Health)—Seniors who receive prescriptions for opioid drugs to control pain after major surgery don’t usually end up addicted to them, research from Canada shows. One year after having major surgery, less than 1% of patients over age 66 were still taking opioids, according to a report in JAMA Surgery. Recent research has suggested the…

Filed under:AnalgesicsDrug Updates Tagged with:AddictionelderlyOpioidsPainPain Managementseniorsurgery

U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller

Reuters Staff  |  August 7, 2016

WASHINGTON (Reuters)—A U.S. advisory panel on Thursday recommended approval of Egalet Corp’s long-acting opioid painkiller, Arymo ER (morphine sulfate), saying it dulls pain and could deter abuse by addicts seeking a quick high. The panel recommended that the U.S. Food and Drug Administration (FDA) approve the drug and said it deters, but does not eliminate,…

Filed under:AnalgesicsDrug Updates Tagged with:abuseAddictionDrugsFDAFood and Drug AdministrationOpioids

U.S. Republicans Reject Democratic Funding Proposals for Opioids

Reuters Staff  |  July 7, 2016

WASHINGTON (Reuters) – Republican lawmakers in U.S. Congress on Wednesday rejected two Democratic amendments to provide nearly $1 billion in funding for bipartisan legislation intended to combat America’s opioid epidemic, aides said. The rejection, which came during a meeting of U.S. House of Representatives and Senate negotiators on the measure, could undermine Democratic support for…

Filed under:Legislation & AdvocacyProfessional Topics

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences